First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
